
Elfriede Bollschweiler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8350566/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comment on "ls Local Endoscopic Resection a Viable Therapeutic Option for Early Clinical Stage T1a and T1b Esophageal Adenocarcinoma? A Propensity-matched Analysis― Annals of Surgery, 2021, 274, e916-e917.	4.2	0
2	External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer. Annals of Surgical Oncology, 2020, 27, 1250-1258.	1.5	6
3	Propensity score–matched comparison between open and minimal invasive hybrid esophagectomy for esophageal adenocarcinoma. Langenbeck's Archives of Surgery, 2020, 405, 521-532.	1.9	6
4	Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by <i>ERCC1</i> or <i>ABCB1</i> . Future Oncology, 2020, 16, 2075-2087.	2.4	2
5	Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients. World Journal of Gastroenterology, 2020, 26, 3236-3248.	3.3	1
6	Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma. Scientific Reports, 2019, 9, 12113.	3.3	12
7	Neoadjuvant chemoradiation for patients with advanced oesophageal cancer – which response grading system best impacts prognostic discrimination?. Histopathology, 2019, 74, 731-743.	2.9	20
8	Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer. Annals of Translational Medicine, 2019, 7, S228-S228.	1.7	3
9	Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4957-4965.	2.4	37
10	Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Annals of the New York Academy of Sciences, 2018, 1434, 132-138.	3.8	64
11	Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer, 2017, 20, 83-91.	5.3	48
12	Current and future treatment options for esophageal cancer in the elderly. Expert Opinion on Pharmacotherapy, 2017, 18, 1001-1010.	1.8	102
13	Somatic BRCA1‑associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. Molecular and Clinical Oncology, 2017, 7, 225-228.	1.0	7
14	High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. Oncotarget, 2017, 8, 115179-115189.	1.8	13
15	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. Journal of Clinical Pathology, 2016, 69, 956-961.	2.0	30
16	Gastric Outlet Obstruction After Esophagectomy: Retrospective Analysis of the Effectiveness and Safety of Postoperative Endoscopic Pyloric Dilatation. World Journal of Surgery, 2016, 40, 2405-2411.	1.6	39
17	The Barrettâ€associated variants at <i><scp>GDF</scp>7</i> and <i><scp>TBX</scp>5</i> also increase esophageal adenocarcinoma risk. Cancer Medicine, 2016, 5, 888-891.	2.8	21
18	Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 549-558.	0.6	33

#	Article	IF	CITATIONS
19	Supportive evidence for <i><scp>FOXP</scp>1</i> , <i><scp>BARX</scp>1</i> , and <i><scp>FOXF</scp>1</i> as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Medicine, 2015, 4, 1700-1704.	2.8	26
20	Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 822-831.	1.5	36
21	Reply to the Comment on: Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – A propensity score matched analysis. Eur J Cancer. 2014;50(17):2950–7. European Journal of Cancer, 2015, 51, 2097-2098.	2.8	0
22	Molecular markers predicting lymph node metastasis in early esophageal cancer. Histology and Histopathology, 2015, 30, 1193-202.	0.7	7
23	Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015. 27. 221-30.	2.2	16
24	GLUT-1 and GLUT-14 as independent prognostic factors in gastric adenocarcinoma Journal of Clinical Oncology, 2015, 33, e15064-e15064.	1.6	0
25	Prognostic impact of blood biomarkers TS and DPD in neoadjuvant-treated esophageal cancer patients. Anticancer Research, 2015, 35, 1297-302.	1.1	2
26	Treatment of early gastric cancer in the Western World. World Journal of Gastroenterology, 2014, 20, 5672.	3.3	58
27	Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World Journal of Gastroenterology, 2014, 20, 5679.	3.3	143
28	What Should Be the Gold Standard for the Surgical Component in the Treatment of Locally Advanced Esophageal Cancer. Annals of Surgery, 2014, 260, 1016-1022.	4.2	93
29	Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – A propensity score matched analysis. European Journal of Cancer, 2014, 50, 2950-2957.	2.8	34
30	Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha. Anticancer Research, 2014, 34, 3313-20.	1.1	9
31	Prognostic relevance of nutritional status in patients with advanced esophageal cancer. Expert Review of Anticancer Therapy, 2013, 13, 275-278.	2.4	12
32	Invited Commentary. Annals of Thoracic Surgery, 2012, 93, 428.	1.3	0
33	Prognostic Significance of a New Grading System of Lymph Node Morphology After Neoadjuvant Radiochemotherapy for Esophageal Cancer. Annals of Thoracic Surgery, 2011, 92, 2020-2027.	1.3	45
34	Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer. Annals of Surgical Oncology, 2010, 17, 3187-3194.	1.5	44
35	Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncology, 2010, 6, 25-35.	2.4	49
36	High Prevalence of Colonic Polyps in White Males with Esophageal Adenocarcinoma. Diseases of the Colon and Rectum, 2009, 52, 299-304.	1.3	19

#	Article	IF	CITATIONS
37	Prevalence of Dysphagia in Patients with Gastroesophageal Reflux in Germany. Dysphagia, 2008, 23, 172-176.	1.8	42
38	Improving Informed Consent of Surgical Patients Using a Multimedia-Based Program?. Annals of Surgery, 2008, 248, 205-211.	4.2	102
39	Staging of esophageal carcinoma: Length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?. Journal of Surgical Oncology, 2006, 94, 355-363.	1.7	137
40	Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer. Annals of Surgery, 2005, 242, 684-692.	4.2	334
41	Evaluation of POSSUM scoring system in patients with gastric cancer undergoing D2-gastrectomy. BMC Surgery, 2005, 5, 8.	1.3	29
42	Bile Reflux into the Stomach and the Esophagus for Volunteers Older than 40 Years. Digestion, 2005, 71, 65-71.	2.3	20
43	Squamous Cell Carcinoma and Adenocarcinoma of the EsophagusDifferences in Etiology, Epidemiology and Prevention. Chinese-German Journal of Clinical Oncology, 2004, 3, 201-204.	0.1	3
44	Impact of a Hospital?s Workload on Clinical Outcome after Resection for Carcinoma of the Esophagus. Chinese-German Journal of Clinical Oncology, 2004, 3, 244-248.	0.1	0
45	Benefits and limitations of Kaplan?Meier calculations of survival chance in cancer surgery. Langenbeck's Archives of Surgery, 2003, 388, 239-244.	1.9	47
46	Vitamin intake and risk of subtypes of esophageal cancer in Germany. Journal of Cancer Research and Clinical Oncology, 2002, 128, 575-580.	2.5	82
47	Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer, 2001, 92, 549-555.	4.1	430